NeuroAge Therapeutics is a woman-founded longevity biotech company that creates drugs to rejuvenate the brain and treat cognitive deficits in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, ALS, and long COVID. Our motivation to found NeuroAge was based on personal experience.

NeuroAge is working on a large postmortem cohort of about 2000 brains, analyzing them using various biological age clocks. The main takeaway is that people whose biological age was younger than their chronological age at death, were less likely to have developed Alzheimer’s. Based on this and other insights, NeuroAge has developed a proprietary platform to identify protein products that are specific to slowing brain aging and eventually develop therapeutics against Alzheimer’s and other protein misfolding diseases.